Cardio Diagnostics Holdings, Inc.

CDIO

$1.83

-0.54%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Negociación activa

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular ...

Cadena de suministro de CDIO

Aguas arriba

Fundiciones, empaquetado, memoria, obleas, componentes y proveedores de insumos.

Aguas arriba

Unnamed Sole Contract Manufacturer (SEC Risk Factor)

Thermo Fisher Scientific Inc.

NYSE:TMO

Supplies TaqMan PCR reagents, assay consumables, and lab instrumentation for CLIA lab operations

Illumina, Inc.

NASDAQ:ILMN

Potential supplier of next-generation sequencing instruments and consumables for epigenetic/genetic biomarker analysis

Qiagen N.V.

NYSE:QGEN

Supplies nucleic acid extraction and sample preparation kits used in PCR-based diagnostic workflows

Cardinal Health, Inc.

NYSE:CAH

Potential distributor of laboratory consumables, blood collection tubes, and medical supplies for at-home sample collection kits

Henry Schein, Inc.

NASDAQ:HSIC

Potential supplier of point-of-care and laboratory supplies, sample collection materials

Aguas abajo

Clientes, distribuidores, OEM y canales que absorben la producción.

Aguas abajo

Vizient, Inc.

Navierre

Family Medicine Specialists, P.C. (FMS)

Dr. Lal PathLabs Limited

Aimil Ltd.

YMCA of East Tennessee

Southdale YMCA (Edina, Minnesota)

Truckers Health Network

Vizient, Inc.

Innovative Technology Contract (Nov 2023) providing access to over 60% of U.S. hospitals and 97% of academic medical centers for procurement of Epi+Gen CHD and PrecisionCHD tests

Navierre

Nationwide telehealth agreement (Apr 2024) enabling patients to request tests via telehealth clinicians for at-home sample collection

Family Medicine Specialists, P.C. (FMS)

Provider partnership placing Cardio Diagnostics tests at select Walmart Supercenter retail healthcare clinics in Illinois (Round Lake Beach, etc.) on a walk-in basis

Dr. Lal PathLabs Limited

NSE:LALPATHLAB

India distribution partner (Jan 2026) — leading Indian diagnostic lab network (~300 labs) launching PrecisionCHD test in the Indian market

Aimil Ltd.

India distribution partner and logistics intermediary (Jan 2026) — longstanding instrumentation distributor facilitating market entry into India alongside Dr. Lal PathLabs

Comparables

Empresas cotizadas comparables y valores de seguimiento usados como representantes del análisis.

Comparables

Quest Diagnostics Incorporated

Exact Sciences Corporation

NASDAQ:EXAS

Molecular diagnostics company that commercialized a novel epigenetics-based cancer screening test (Cologuard) from academic origins — similar go-to-market model of CLIA lab + test kit + reimbursement strategy as CDIO aims for.

Veracyte, Inc.

NASDAQ:VCYT

Genomic diagnostics company using molecular tests for thyroid, lung, and breast cancer. Similar model of proprietary lab-developed tests with insurance reimbursement, AI/ML integration, and academic spinout origin.

Guardant Health, Inc.

NASDAQ:GH

Precision oncology liquid biopsy company with CLIA lab operations. Proxy for blood-based molecular diagnostic commercial model with similar upstream reliance on sequencing/reagent supply chain.

Natera, Inc.

NASDAQ:NTRA

Genetic testing and diagnostics company with CLIA labs, offering cell-free DNA tests. Comparable business model of proprietary blood-based molecular diagnostics with employer/population health offerings.

Quest Diagnostics Incorporated

NYSE:DGX

Established laboratory services provider — represents the downstream partner archetype that CDIO's tests flow through. Also a potential acquirer in the cardiovascular diagnostics space.

Geografía

Exposiciones regionales que pueden distorsionar la red de suministro.

Geografía

United States (primary market)

India (first international expansion)

Vizient, Inc.

Navierre

Family Medicine Specialists / Walmart

Dr. Lal PathLabs Limited

Aimil Ltd.

United States (primary market)

Domestic market concentration — all current operations and most partnerships are US-based

Vizient, Inc.Hospital GPO contracting partner for US market

NavierreUS telehealth platform partner

Family Medicine Specialists / WalmartRetail clinic partner in Illinois

India (first international expansion)

Geographic expansion risk via Aimil Ltd. and Dr. Lal PathLabs partnership (Jan 2026). Regulatory, currency, and operational execution risk in a new market.

Dr. Lal PathLabs LimitedNSE:LALPATHLABIndian lab network distribution partner

Aimil Ltd.Indian instrumentation/logistics distributor

Concentración

Exposiciones de concentración de clientes, proveedores o socios que pueden distorsionar la red de suministro.

Customer

Critical

Extreme customer concentration risk: Company is pre-commercial ($15K annual revenue) with no single customer generating material revenue. Heavy dependence on nascent channel partners (Vizient, Navierre, Dr. Lal PathLabs) to scale.

Equipment

High

PCR/reagent supply dependency: CDIO's proprietary tests use TaqMan PCR assays. Any disruption in PCR reagent supply, particularly from key suppliers like Thermo Fisher, would halt testing operations at the CLIA lab.

Other

Critical

Reimbursement concentration risk: Tests currently rely on CMS reimbursement (CPT code pricing ~$854 per test). Denial or reduction of coverage would materially impact the business model.

Composición de ingresos

Cómo la composición de ingresos se traduce en apalancamiento y dependencia en la cadena de suministro.

Epi+Gen CHD (3-year CHD risk assessment test)

40.0%

Pre-commercial; relies on PCR reagents and sample collection kit supply chain. Limited volumes drive minimal upstream procurement.

PrecisionCHD (CHD diagnostic and management test)

40.0%

Pre-commercial; requires same PCR/reagent inputs as Epi+Gen CHD. India launch via Aimil/Dr. Lal PathLabs in early 2026.

HeartRisk (employer/population health platform)

15.0%

Software/data analytics layer over test results; minimal physical supply chain. Drives downstream demand for testing kits.

Other / Pilot Programs

5.0%

Minimal; pilot-scale volumes only.

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Cardio Diagnostics Holdings, Inc.

Cadena de suministro de CDIO

Aguas arriba

Thermo Fisher Scientific Inc.

Illumina, Inc.

Qiagen N.V.

Cardinal Health, Inc.

Henry Schein, Inc.

Unnamed Sole Contract Manufacturer (SEC Risk Factor)

Aguas abajo

Vizient, Inc.

Navierre

Family Medicine Specialists, P.C. (FMS)

Dr. Lal PathLabs Limited

Aimil Ltd.

YMCA of East Tennessee

Southdale YMCA (Edina, Minnesota)

Truckers Health Network

View More

Comparables

Exact Sciences Corporation

Veracyte, Inc.

Guardant Health, Inc.

Natera, Inc.

Quest Diagnostics Incorporated

Geografía

United States (primary market)

India (first international expansion)

Cadena de suministro de CDIO

Aguas arriba

Thermo Fisher Scientific Inc.

Illumina, Inc.

Qiagen N.V.

Cardinal Health, Inc.

Henry Schein, Inc.

Unnamed Sole Contract Manufacturer (SEC Risk Factor)

Aguas abajo

Vizient, Inc.

Navierre

Family Medicine Specialists, P.C. (FMS)

Dr. Lal PathLabs Limited

Aimil Ltd.

YMCA of East Tennessee

Southdale YMCA (Edina, Minnesota)

Truckers Health Network

View More

Comparables

Exact Sciences Corporation

Veracyte, Inc.

Guardant Health, Inc.

Natera, Inc.

Quest Diagnostics Incorporated

Geografía

United States (primary market)

India (first international expansion)